• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Long-term survival after multidisciplinary treatments for advanced esophagogastric junction cancer.晚期食管胃交界癌多学科治疗后的长期生存情况。
Int Cancer Conf J. 2021 Apr 8;10(3):207-211. doi: 10.1007/s13691-021-00480-4. eCollection 2021 Jul.
2
Five-year Survival After Surgical Removal and Gamma Knife Stereotactic Radiosurgery for a Cerebellar Metastasis from an Esophagogastric Junction Cancer: A Case Report and Literature Review.食管胃交界癌小脑转移瘤手术切除及伽玛刀立体定向放射治疗后的五年生存率：一例报告及文献综述
In Vivo. 2017 Nov-Dec;31(6):1209-1214. doi: 10.21873/invivo.11192.
3
[A Case of Successful Multidisciplinary Therapy for Advanced Esophagogastric Junction Cancer with Multiple Lymph Node Metastase].[1例晚期食管胃交界部癌伴多发淋巴结转移的多学科成功治疗病例]
Gan To Kagaku Ryoho. 2016 Nov;43(12):2010-2012.
4
Multimodal Treatment With Nivolumab Contributes to Long-Term Survival in a Case of Unresectable Esophagogastric Junction Neuroendocrine Carcinoma.纳武利尤单抗多模式治疗有助于不可切除的食管胃交界部神经内分泌癌患者长期生存。
Cureus. 2024 Aug 1;16(8):e65981. doi: 10.7759/cureus.65981. eCollection 2024 Aug.
5
A long-term survivor of recurrent esophagogastric junction adenocarcinoma treated with multidisciplinary therapy: a case report.多学科治疗复发性食管胃交界腺癌的长期幸存者：一例报告
Surg Case Rep. 2020 Jan 9;6(1):13. doi: 10.1186/s40792-020-0776-5.
6
Comparison of mediastinal lymph node metastases from adenocarcinoma of the esophagogastric junction versus lower esophageal squamous cell carcinoma with involvement of the esophagogastric junction.胃食管结合部腺癌与累及胃食管结合部的下段食管鳞癌纵隔淋巴结转移的比较。
Dis Esophagus. 2019 Dec 30;32(11). doi: 10.1093/dote/doz002.
7
Pathological Complete Response and Successful Conversion Surgery After Nivolumab Therapy for Stage IV Oesophagogastric Junction Cancer.纳武利尤单抗治疗 IV 期食管胃结合部癌后获得病理完全缓解并成功改行手术治疗。
In Vivo. 2021 Jul-Aug;35(4):2247-2251. doi: 10.21873/invivo.12497.
8
[Neoadjuvant chemoradiotherapy combined with surgery versus direct surgery in the treatment of Siewert type II and III adenocarcinomas of the esophagogastric junction: long-term prognostic analysis of a prospective randomized controlled trial].新辅助放化疗联合手术与直接手术治疗食管胃交界部SiewertⅡ型和Ⅲ型腺癌：一项前瞻性随机对照试验的长期预后分析
Zhonghua Wei Chang Wai Ke Za Zhi. 2021 Feb 25;24(2):128-137. doi: 10.3760/cma.j.cn.441530-20201019-00565.
9
Long-term survival following radical surgery after chemotherapy for esophagogastric adenocarcinoma with extensive lymph node metastases: report of a case.化疗后行根治性手术治疗广泛淋巴结转移的胃食管腺癌长期生存 1 例报告
Surg Today. 2011 Sep;41(9):1255-9. doi: 10.1007/s00595-010-4463-1. Epub 2011 Aug 26.
10
[A Case of Long-Term Survival without Recurrence after Completion of Immunotherapy Due to Response of Third- Line Nivolumab for Liver Metastasis Recurrence of Esophagogastric Junction Cancer].[一例因三线纳武单抗治疗食管胃交界癌肝转移复发有效而完成免疫治疗后长期无复发存活的病例]
Gan To Kagaku Ryoho. 2023 Oct;50(10):1126-1129.

本文引用的文献

1
International Retrospective Cohort Study of Conversion Therapy for Stage IV Gastric Cancer 1 (CONVO-GC-1).IV期胃癌转化治疗的国际回顾性队列研究1（CONVO-GC-1）。
Ann Gastroenterol Surg. 2021 Oct 20;6(2):227-240. doi: 10.1002/ags3.12515. eCollection 2022 Mar.
2
Gastrectomy Versus Esophagectomy for Gastroesophageal Junction Tumors: Short- and Long-Term Outcomes From the Dutch Upper Gastrointestinal Cancer Audit.胃切除术与食管切除术治疗胃食管结合部肿瘤：荷兰上消化道癌症审计的短期和长期结果。
Ann Surg. 2022 Dec 1;276(6):e735-e743. doi: 10.1097/SLA.0000000000004610. Epub 2020 Nov 17.
3
The role of surgery and radiation in advanced gastric cancer: A population-based study of Surveillance, Epidemiology, and End Results database.手术和放疗在晚期胃癌中的作用：基于监测、流行病学和最终结果数据库的一项人群研究。
PLoS One. 2019 Mar 12;14(3):e0213596. doi: 10.1371/journal.pone.0213596. eCollection 2019.
4
Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries.全球癌症生存趋势监测 2000-14 年（CONCORD-3）：对来自 71 个国家 322 个基于人群的登记处的 37513025 名诊断患有 18 种癌症之一的患者的个体记录进行分析。
Lancet. 2018 Mar 17;391(10125):1023-1075. doi: 10.1016/S0140-6736(17)33326-3. Epub 2018 Jan 31.
5
The RENAISSANCE (AIO-FLOT5) trial: effect of chemotherapy alone vs. chemotherapy followed by surgical resection on survival and quality of life in patients with limited-metastatic adenocarcinoma of the stomach or esophagogastric junction - a phase III trial of the German AIO/CAO-V/CAOGI.RENAISSANCE (AIO-FLOT5) 试验：单纯化疗与化疗后手术切除对局限转移性胃或胃食管交界部腺癌患者生存和生活质量的影响——德国 AIO/CAO-V/CAOGI 多中心、开放标签、III 期临床试验
BMC Cancer. 2017 Dec 28;17(1):893. doi: 10.1186/s12885-017-3918-9.
6
Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial.纳武利尤单抗治疗既往至少两种化疗方案治疗失败或不耐受的晚期胃或胃食管结合部腺癌患者（ONO-4538-12，ATTRACTION-2）：一项随机、双盲、安慰剂对照、III 期临床试验。
Lancet. 2017 Dec 2;390(10111):2461-2471. doi: 10.1016/S0140-6736(17)31827-5. Epub 2017 Oct 6.
7
Conversion therapy for gastric cancer: who can make conversion as successful as Goromaru?胃癌的转化治疗：谁能使转化治疗像Goromaru那样成功？
Gastric Cancer. 2016 Jul;19(3):685-6. doi: 10.1007/s10120-016-0609-1. Epub 2016 Apr 7.
8
Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): a phase 3, randomised controlled trial.胃切除术加化疗与单纯化疗治疗有单一不可治愈因素的晚期胃癌（REGATTA）：一项 3 期随机对照试验。
Lancet Oncol. 2016 Mar;17(3):309-318. doi: 10.1016/S1470-2045(15)00553-7. Epub 2016 Jan 26.
9
Influence of Surgical Resection of Hepatic Metastases From Gastric Adenocarcinoma on Long-term Survival: Systematic Review and Pooled Analysis.胃腺癌肝转移灶手术切除对长期生存的影响：系统评价与汇总分析
Ann Surg. 2016 Jun;263(6):1092-101. doi: 10.1097/SLA.0000000000001542.
10
Is conversion therapy possible in stage IV gastric cancer: the proposal of new biological categories of classification.IV期胃癌是否可行转化治疗：新的生物学分类范畴建议
Gastric Cancer. 2016 Apr;19(2):329-338. doi: 10.1007/s10120-015-0575-z. Epub 2015 Dec 7.

晚期食管胃交界癌多学科治疗后的长期生存情况。

Long-term survival after multidisciplinary treatments for advanced esophagogastric junction cancer.

作者信息

Matsumoto Chihiro, Iwatsuki Masaaki, Morinaga Takeshi, Yamashita Kohei, Nakamura Kenichi, Kurashige Junji, Eto Kojiro, Iwagami Shiro, Baba Yoshifumi, Yoshida Naoya, Miyamoto Yuji, Baba Hideo

机构信息

Department of Gastroenterological Surgery, Graduate School of Medical Sciences, Kumamoto University, 1-1-1 Honjo, Chuo-ku, Kumamoto-City, 860-8556 Japan.

出版信息

Int Cancer Conf J. 2021 Apr 8;10(3):207-211. doi: 10.1007/s13691-021-00480-4. eCollection 2021 Jul.

DOI:10.1007/s13691-021-00480-4
PMID:34221833
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8206417/
Abstract

Stage IV Gastric/Esophagogastric junction cancer (G/EGJ) has an unfavorable prognosis and poor curability. In this study, we report the case of long-term survival after multidisciplinary treatments for advanced esophagogastric junction cancer. A 53-year-old male patient was diagnosed with HER2 positive advanced esophagogastric junction cancer and mediastinal and paraaortic lymph node metastasis. After systemic chemotherapy for 1 year, minimally invasive esophagectomy was conducted as conversion surgery. However, peritoneal and liver metastasis was observed on 3 months after curative surgery. 2 years after operation, solitary brain metastasis was detected and stereotactic radiosurgery (SRS) using a gamma knife was underwent. After 1 year, despite the continuous administration of Nivolumab, the paraaortic lymph node increased in size again and radiation therapy was conducted. Currently, he is alive and undergoing chemotherapy.

摘要

IV期胃/食管胃交界部癌（G/EGJ）预后不良，治愈率低。在本研究中，我们报告了1例晚期食管胃交界部癌多学科治疗后长期生存的病例。一名53岁男性患者被诊断为HER2阳性晚期食管胃交界部癌伴纵隔及腹主动脉旁淋巴结转移。全身化疗1年后，行微创食管切除术作为转化手术。然而，根治性手术后3个月发现腹膜和肝转移。术后2年，检测到孤立性脑转移，接受了伽玛刀立体定向放射外科治疗（SRS）。1年后，尽管持续使用纳武单抗，腹主动脉旁淋巴结再次增大，遂进行放射治疗。目前，他仍存活并正在接受化疗。